340 related articles for article (PubMed ID: 22004131)
1. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.
Price MA; Colvin Wanshura LE; Yang J; Carlson J; Xiang B; Li G; Ferrone S; Dudek AZ; Turley EA; McCarthy JB
Pigment Cell Melanoma Res; 2011 Dec; 24(6):1148-57. PubMed ID: 22004131
[TBL] [Abstract][Full Text] [Related]
2. Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain.
Yang J; Price MA; Wanshura LEC; He J; Yi M; Welch DR; Li G; Conner S; Sachs J; Turley EA; McCarthy JB
Melanoma Res; 2019 Aug; 29(4):365-375. PubMed ID: 31140988
[TBL] [Abstract][Full Text] [Related]
3. Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
Pucciarelli D; Lengger N; Takacova M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
Int J Oncol; 2015 Jul; 47(1):81-90. PubMed ID: 25997619
[TBL] [Abstract][Full Text] [Related]
4. Detection of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma.
Wang Y; Sabbatino F; Wang X; Ferrone S
Methods Mol Biol; 2014; 1102():523-35. PubMed ID: 24258997
[TBL] [Abstract][Full Text] [Related]
5. Chondroitin sulfate proteoglycan-4 does not protect melanoma cells during inhibition of PI3K and mTOR pathways.
Javaid S; Terai K; Dudek AZ
Anticancer Res; 2015 Mar; 35(3):1279-84. PubMed ID: 25750275
[TBL] [Abstract][Full Text] [Related]
6. CSPG4: a prototype oncoantigen for translational immunotherapy studies.
Rolih V; Barutello G; Iussich S; De Maria R; Quaglino E; Buracco P; Cavallo F; Riccardo F
J Transl Med; 2017 Jul; 15(1):151. PubMed ID: 28668095
[TBL] [Abstract][Full Text] [Related]
7. Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma.
Mayayo SL; Prestigio S; Maniscalco L; Rosa G; Aricò A; Maria R; Cavallo F; Ferrone S; Buracco P; Iussich S
Vet J; 2011 Nov; 190(2):e26-e30. PubMed ID: 21482159
[TBL] [Abstract][Full Text] [Related]
8. Functional and clinical relevance of chondroitin sulfate proteoglycan 4.
Campoli M; Ferrone S; Wang X
Adv Cancer Res; 2010; 109():73-121. PubMed ID: 21070915
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4.
Wang X; Katayama A; Wang Y; Yu L; Favoino E; Sakakura K; Favole A; Tsuchikawa T; Silver S; Watkins SC; Kageshita T; Ferrone S
Cancer Res; 2011 Dec; 71(24):7410-22. PubMed ID: 22021902
[TBL] [Abstract][Full Text] [Related]
10. Structural deciphering of the NG2/CSPG4 proteoglycan multifunctionality.
Tamburini E; Dallatomasina A; Quartararo J; Cortelazzi B; Mangieri D; Lazzaretti M; Perris R
FASEB J; 2019 Mar; 33(3):3112-3128. PubMed ID: 30550356
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma.
Grossauer A; Uranowska K; Kitzwögerer M; Mostegel M; Breiteneder H; Hafner C
Oncol Lett; 2023 Sep; 26(3):382. PubMed ID: 37559576
[TBL] [Abstract][Full Text] [Related]
12. Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.
Kurokawa T; Imai K
Proc Jpn Acad Ser B Phys Biol Sci; 2024; 100(5):293-308. PubMed ID: 38735753
[TBL] [Abstract][Full Text] [Related]
13. Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
Hsu SC; Nadesan P; Puviindran V; Stallcup WB; Kirsch DG; Alman BA
J Biol Chem; 2018 Feb; 293(7):2466-2475. PubMed ID: 29196603
[TBL] [Abstract][Full Text] [Related]
14. Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.
Eng MS; Kaur J; Prasmickaite L; Engesæter BØ; Weyergang A; Skarpen E; Berg K; Rosenblum MG; Mælandsmo GM; Høgset A; Ferrone S; Selbo PK
Photochem Photobiol Sci; 2018 May; 17(5):539-551. PubMed ID: 29565434
[TBL] [Abstract][Full Text] [Related]
15. Chondroitin sulfate proteoglycan 4 functions as the cellular receptor for Clostridium difficile toxin B.
Yuan P; Zhang H; Cai C; Zhu S; Zhou Y; Yang X; He R; Li C; Guo S; Li S; Huang T; Perez-Cordon G; Feng H; Wei W
Cell Res; 2015 Feb; 25(2):157-68. PubMed ID: 25547119
[TBL] [Abstract][Full Text] [Related]
16. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.
Geldres C; Savoldo B; Hoyos V; Caruana I; Zhang M; Yvon E; Del Vecchio M; Creighton CJ; Ittmann M; Ferrone S; Dotti G
Clin Cancer Res; 2014 Feb; 20(4):962-71. PubMed ID: 24334762
[TBL] [Abstract][Full Text] [Related]
17. Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4.
Chauhan J; Grandits M; Palhares LCGF; Mele S; Nakamura M; López-Abente J; Crescioli S; Laddach R; Romero-Clavijo P; Cheung A; Stavraka C; Chenoweth AM; Sow HS; Chiaruttini G; Gilbert AE; Dodev T; Koers A; Pellizzari G; Ilieva KM; Man F; Ali N; Hobbs C; Lombardi S; Lionarons DA; Gould HJ; Beavil AJ; Geh JLC; MacKenzie Ross AD; Healy C; Calonje E; Downward J; Nestle FO; Tsoka S; Josephs DH; Blower PJ; Karagiannis P; Lacy KE; Spicer J; Karagiannis SN; Bax HJ
Nat Commun; 2023 Apr; 14(1):2192. PubMed ID: 37185332
[TBL] [Abstract][Full Text] [Related]
18. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.
Wang Y; Geldres C; Ferrone S; Dotti G
Expert Opin Ther Targets; 2015; 19(10):1339-50. PubMed ID: 26190756
[TBL] [Abstract][Full Text] [Related]
19. Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma.
Teppert K; Winter N; Herbel V; Brandes C; Lennartz S; Engert F; Kaiser A; Schaser T; Lock D
Front Immunol; 2023; 14():1178060. PubMed ID: 37901209
[TBL] [Abstract][Full Text] [Related]
20. Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.
Riccardo F; Tarone L; Camerino M; Giacobino D; Iussich S; Barutello G; Arigoni M; Conti L; Bolli E; Quaglino E; Merighi IF; Morello E; Dentini A; Ferrone S; Buracco P; Cavallo F
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
